Cargando…

Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab

BACKGROUND: We hypothesized that elevations of plasma Oncostatin M (OSM) would be associated with infliximab nonresponse. METHODS: Plasma OSM was measured in Crohn disease patients pre-infliximab with biochemical response (>50% reduction in fecal calprotectin) as the primary outcome. RESULTS: The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minar, Phillip, Lehn, Christina, Tsai, Yi-Ting, Jackson, Kimberly, Rosen, Michael J, Denson, Lee A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Observations And Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798793/ https://www.ncbi.nlm.nih.gov/pubmed/31667468 http://dx.doi.org/10.1093/crocol/otz026

Ejemplares similares

Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease
por: Hellmann, Jennifer, et al.
Publicado: (2021)

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States
por: Smith, Joshua T, et al.
Publicado: (2021)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction
por: Normatov, Inessa, et al.
Publicado: (2021)

Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis
por: O’Connell, Jim, et al.
Publicado: (2022)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China
por: Shi, Ji-Hao, et al.
Publicado: (2020)

Ideal Vial Size for Infliximab in the Treatment of Inflammatory Bowel Disease: An Analysis of Pharmaceutical Waste and Physician Opinions
por: Schachne, Jonathan M, et al.
Publicado: (2021)

HIV-1 Is a Poor Inducer of Innate Immune Responses
por: Cingöz, Oya, et al.
Publicado: (2019)

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study
por: Viola, Anna, et al.
Publicado: (2017)

Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center
por: Gagnon, Ann-Lorie, et al.
Publicado: (2021)

Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma
por: Liu, Peng, et al.
Publicado: (2015)

Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring
por: Syed, Nauroz, et al.
Publicado: (2020)

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
por: Pierik, Marieke J, et al.
Publicado: (2021)

Highly Elevated Plasma γ‐Glutamyltransferase Elevations: A Trait Caused by γ‐Glutamyltransferase 1 Transmembrane Mutations
por: De Grandi, Alessandro, et al.
Publicado: (2019)

Early Start of Infliximab in Crohn’s Disease Increases Rates of Endoscopic Remission and Decreases Stenosis Formation: Experiences From a Single Center Cohort
por: Schnitzler, Fabian, et al.
Publicado: (2021)

Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study
por: Abushamma, Suha, et al.
Publicado: (2023)

Multifaceted oncostatin M: novel roles and therapeutic potential of the oncostatin M signaling in rheumatoid arthritis
por: Han, Liang, et al.
Publicado: (2023)

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
por: Ducourau, Emilie, et al.
Publicado: (2011)

Inactivation of a Foodborne Norovirus Outbreak Strain with Nonthermal Atmospheric Pressure Plasma
por: Ahlfeld, Birte, et al.
Publicado: (2015)

Zika Virus Is Not Uniquely Stable at Physiological Temperatures Compared to Other Flaviviruses
por: Goo, Leslie, et al.
Publicado: (2016)

Elevated Fecal pH Indicates a Profound Change in the Breastfed Infant Gut Microbiome Due to Reduction of Bifidobacterium over the Past Century
por: Henrick, Bethany M., et al.
Publicado: (2018)

DHCR7 Expression Predicts Poor Outcomes and Mortality From Sepsis
por: Guirgis, Faheem W., et al.
Publicado: (2023)

Oncostatin M Modulation of Lipid Storage
por: Elks, Carrie M., et al.
Publicado: (2015)

Hyperkeratotic necrobiosis lipoidica
por: Khan, Farhan, et al.
Publicado: (2013)

Histiocytoid Sweet’s syndrome in a patient with myelodsyplastic syndrome: report and review of the literature
por: Shalaby, Michael M., et al.
Publicado: (2016)

Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment
por: Karaba, Andrew H., et al.
Publicado: (2023)

The vanR(Cd) Mutation 343A>G, Resulting in a Thr115Ala Substitution, Is Associated with an Elevated Minimum Inhibitory Concentration (MIC) of Vancomycin in Clostridioides difficile Clinical Isolates from Florida
por: Wickramage, Ishani, et al.
Publicado: (2023)

The Enigmatic Cytokine Oncostatin M and Roles in Disease
por: Richards, Carl D.
Publicado: (2013)

Oncostatin M promotes lipolysis in white adipocytes
por: van Krieken, Pim P., et al.
Publicado: (2022)

Pretreatment Vitamin D Concentrations Do Not Predict Therapeutic Outcome to Anti-TNF Therapies in Biologic-Naïve Patients With Active Luminal Crohn’s Disease
por: Chanchlani, Neil, et al.
Publicado: (2023)

Calcium Promotes T6SS-Mediated Killing and Aggregation between Competing Symbionts
por: Speare, Lauren, et al.
Publicado: (2022)

The Type a and Type b Polysaccharide Capsules Predominate in an International Collection of Invasive Kingella kingae Isolates
por: Porsch, Eric A., et al.
Publicado: (2017)

Investigation of the Plasma Virome from Cases of Unexplained Febrile Illness in Tanzania from 2013 to 2014: a Comparative Analysis between Unbiased and VirCapSeq-VERT High-Throughput Sequencing Approaches
por: Williams, Simon H., et al.
Publicado: (2018)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Difference and clinical value of metabolites in plasma and feces of patients with alcohol-related liver cirrhosis
por: Xu, Yi-Fan, et al.
Publicado: (2023)

Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716
por: RICHARDS, Carl D., et al.
Publicado: (2020)

Solitary trichoepithelioma in an 8-year-old child: clinical, dermoscopic and histopathologic findings
por: Lazaridou, Elizabeth, et al.
Publicado: (2014)

Overexpression of Ubiquilin4 is associated with poor prognosis in patients with cervical cancer
por: Wang, Li-Na, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qslfqp65cm6dacsin5fm5jnbe7